Vildagliptin (VLD) is a potent, selective dipeptidyl peptidase-IV inhibitor that is approved as an oral treatment of type-II diabetes.1 VLD acts through the prevention of incretin inactivation, which in turn provokes glucose-dependent insulin release and decreases glucagon levels, thus achieving better glycemic control.2 It is effective, with few adverse effects, either alone or in conjunction with other anti-diabetic drugs.3 VLD is 20–25% excreted unaltered in urine within 24 hours.4 Here, GCG is linked to type 2 diabetes mellitus.